Photorealistic depiction of DHX29 protein selectively silencing inefficient mRNA codons in a human cell, illustrating new gene expression research.
Photorealistic depiction of DHX29 protein selectively silencing inefficient mRNA codons in a human cell, illustrating new gene expression research.
Àwòrán tí AI ṣe

Study identifies DHX29 as a key factor linking codon choice to selective silencing of inefficient genetic messages in human cells

Àwòrán tí AI ṣe
Ti ṣayẹwo fun ododo

Researchers at Kyoto University and RIKEN report that human cells can detect “non-optimal” synonymous codons—alternative three-letter genetic instructions that encode the same amino acid but are translated less efficiently—and selectively suppress the corresponding mRNAs. In experiments described in Science, the team identifies the RNA-binding protein DHX29 as a central component of this codon-dependent control of gene expression.

Human genes are read in three-letter nucleotide units called codons, which direct cells to add specific amino acids when building proteins. Although multiple codons can encode the same amino acid, prior research has suggested these “synonymous” codons can behave differently: some are associated with more efficient translation and greater mRNA stability, while others—often described as non-optimal—are translated less efficiently and are more prone to degradation.

To investigate how human cells respond to these differences, a Kyoto University–RIKEN team led by Osamu Takeuchi and Takuhiro Ito conducted a series of experiments, beginning with a genome-wide CRISPR screen to identify regulators of codon-dependent gene expression. The screen pointed to DHX29, an RNA-binding protein, as a key factor.

Follow-up RNA sequencing indicated that when DHX29 is absent, mRNAs enriched in non-optimal codons increase in abundance, consistent with a role for DHX29 in suppressing or destabilizing those messages. The researchers also used cryo-electron microscopy to visualize DHX29 interacting with the 80S ribosome, and selective ribosome profiling suggested DHX29 is more frequently associated with ribosomes decoding non-optimal codons.

Additional proteomic analyses reported by the team found that DHX29 recruits the GIGYF2•4EHP complex, which can repress translation of target mRNAs. In a statement released with the findings, co-corresponding author Masanori Yoshinaga said the results point to a direct molecular link between synonymous codon choice and the control of gene expression in human cells.

The work, published in Science as “Human DHX29 detects nonoptimal codon usage to regulate mRNA stability,” adds to evidence that codon choice can function as a regulatory layer influencing gene output, and the researchers said they plan to further examine how this mechanism operates in health and disease.

Awọn iroyin ti o ni ibatan

Scientist in lab studying bacterial production of HDAC inhibitor cancer drug variants through molecular mix-and-match mechanism.
Àwòrán tí AI ṣe

Scientists map a ‘mix-and-match’ bacterial mechanism behind variants of a cancer drug family

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

Researchers at the University of Warwick report they have identified how bacteria can reliably produce multiple versions of certain histone deacetylase (HDAC) inhibitor compounds, a finding they say could help scientists engineer new drug candidates inspired by these natural products.

A single mRNA injection can halve the rate of chromosome errors in human eggs from older women, according to new research presented at a London conference. The treatment targets a protein deficiency that contributes to aneuploidy, a common cause of IVF failure and miscarriage. Researchers say the approach shows promise for improving fertility outcomes.

Ti AI ṣe iroyin

Researchers have identified the gene NANOG as the key switch that initiates the developmental program resulting in cells forming a human body. The finding came from precise DNA edits to fertilized human eggs using CRISPR base editing.

A protein called NFIL3 has been identified as a key factor in reducing the long-term performance of CAR T cells used in cancer treatment. Researchers showed that disabling this protein allows the engineered cells to remain active longer and fight tumors more effectively in laboratory models.

Ti AI ṣe iroyin Ti ṣayẹwo fun ododo

Researchers at Rockefeller University report that a new single-cell screening platform, PerturbFate, can trace how many different genetic disruptions converge on common regulatory programs that drive resistance to the melanoma drug vemurafenib, pointing to potential combination-therapy targets.

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ